News

Elizabeth Buzney, MD, provides her advice for practice setup, prior authorization timelines, and patient counseling for afamelanotide treatment in erythropoietic protoporphyria.

A new qualitative study finds that patients with hard-to-heal wounds routinely engage in protective and monitoring behaviors at home without recognizing those efforts as meaningful contributions to their own care.

The 3-phase Isoclear regimen pairs topical isotretinoin with clindamycin, tranexamic acid, niacinamide, and copper peptide based on treatment stage.

Before Revolutionizing Atopic Dermatitis 2026 begins, take a look back at the data, debates, and patient stories that defined last year’s Nashville meeting.

Microneedle SkinJect patch aims to clear basal cell carcinoma without surgery, showing phase 2 promise and expanding to Gorlin syndrome trials.

Innovations in packaging, formulation design, and alternative preservation strategies may reduce preservative concentrations, but they are unlikely to eliminate the need for preservatives entirely.

Dissolvable microneedles deliver doxorubicin to basal cell lesions, showing promising phase 2 clearance and opening hope for Gorlin syndrome patients.

Nearly 68% of AD patients and 78% of psoriasis patients on topical-only regimens expressed a desire for systemic therapy, reflecting widespread skepticism about topicals as a long-term strategy.

Avalo readies long-acting AVTX-010 to target hidradenitis suppurativa, aiming for fewer injections for patients after strong phase 2 abdakibart results.

HCW9302 selectively expands Treg cells to suppress autoreactive follicular inflammation without broad immunosuppression.

Michael Ingrassia, PhD, and Ida Wong, MBA, speak about the brand's new line, pairing clinically tested soothing skin care with makeup to calm reactive skin, strengthen the barrier, and ease redness-related stress.

In a pivotal trial, two-thirds of skinvive neck patients maintained clinically significant improvement at six months.

Data from the BroADen trial suggest that targeting STAT6 through protein degradation may offer a novel oral approach to controlling type 2 inflammation in atopic dermatitis.

Cosibelimab joins cemiplimab and pembrolizumab as a first-line option for advanced cSCC unsuitable for curative surgery or radiation.

As Darrell Rigel, MD, MS, notes, bemotrizinol will deliver photostable broad-spectrum UVA/UVB protection with better cosmetic feel, low absorption, and pave the way for more advanced US sunscreens.

IL-4Rα blocker stapokibart cleared chronic spontaneous urticaria and improved quality of life after omalizumab failure in a 44-year-old female patient.

SkinJect demonstrated 64% clinical clearance and 55% complete histological response in a phase 2 study of nodular BCC patients.

Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.

Does this structured nighttime skin care routine actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Learn how today’s aesthetic care is shifting to prevention through skin care, retinoids, lasers, and conservative fillers for natural, refreshed aging.

In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.

The review emphasizes that psychological stress can influence inflammatory pathways involved in CSU, potentially worsening disease activity.

Jared Gollob, MD, chief medical officer at Kymera Therapeutics, discusses early efficacy signals, the phase 2b study design, and the potential clinical role of KT-621, an oral STAT6 degrader, for moderate to severe atopic dermatitis.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Elizabeth Buzney, MD, explains her approach to monitoring patients with erythropoietic protoporphyria using afamelanotide, including skin surveillance, liver function testing, seasonal treatment decisions, and sun protection counseling.

William Posten, MD, provides an overview of postoperative radiation therapy as a treatment for keloids, including dosing parameters, safety considerations, and insurance reimbursement trends.

Amy Snow, MSPAS, PA-C, speaks about her collaboration with wellness influencer to fight TikTok skin care myths and share diet-smart acne tips for teens.

Younger patients are embracing preventative injectables and skin care; Shawna Jones, PA-C, urges evidence-based, personalized plans to cut through social-media hype.

A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.

More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.